Mobble
Health · Cancer research · published 2026-08-17 · via Endpoints News

AstraZeneca terminates Phase 3 volrustomig study following lung cancer failure

AstraZeneca has discontinued a Phase 3 trial of its investigational cancer drug volrustomig after a disappointing outcome in lung cancer. The company announced the decision on Monday, marking another recent setback for its oncology pipeline. No further details on the trial's results were provided.

Read the full article at Endpoints News →
Related stories
AstraZeneca halts late-stage lung cancer trial; U.S. drug prices decline · Cancer research
AstraZeneca reports positive late-stage results for two lung cancer therapies · Cancer research
Zipalertinib succeeds in Phase 3 trial for EGFR-mutant lung cancer, challenging Rybrevant · Cancer research
Definium Therapeutics' oral LSD candidate succeeds in initial Phase 3 trial for generalized anxiety disorder · Mental health
This summary is AI-generated and original to Mobble; the linked article is the authoritative source. Original headline: “AstraZeneca cans late-stage volrustomig trial after lung cancer setback.” Browse more stories.